The Experts below are selected from a list of 75882 Experts worldwide ranked by ideXlab platform
Yu Zong Chen - One of the best experts on this subject based on the ideXlab platform.
-
therapeutic Target Database update 2016 enriched resource for bench to clinical drug Target and Targeted pathway information
Nucleic Acids Research, 2016Co-Authors: Feng Xu, Hong Yang, Ying Hong Li, Jin Zhou, Chun Yan Yu, Zhe Chen, Yu Zong ChenAbstract:Extensive drug discovery efforts have yielded many approved and candidate drugs Targeting various Targets in different biological pathways. Several freely accessible Databases provide the drug, Target and drug-Targeted pathway information for facilitating drug discovery efforts, but there is an insufficient coverage of the clinical trial drugs and the drug-Targeted pathways. Here, we describe an update of the Therapeutic Target Database (TTD) previously featured in NAR. The updated contents include: (i) significantly increased coverage of the clinical trial Targets and drugs (1.6 and 2.3 times of the previous release, respectively), (ii) cross-links of most TTD Target and drug entries to the corresponding pathway entries of KEGG, MetaCyc/BioCyc, NetPath, PANTHER pathway, Pathway Interaction Database (PID), PathWhiz, Reactome and WikiPathways, (iii) the convenient access of the multiple Targets and drugs cross-linked to each of these pathway entries and (iv) the recently emerged approved and investigative drugs. This update makes TTD a more useful resource to complement other Databases for facilitating the drug discovery efforts. TTD is accessible at http://bidd.nus.edu.sg/group/ttd/ttd.asp.
-
The Therapeutic Target Database: an internet resource for the primary Targets of approved, clinical trial and experimental drugs.
Expert opinion on therapeutic targets, 2011Co-Authors: Xin Liu, Lin Tao, Jingxian Zhang, Feng Zhu, Sheng Yong Yang, Yu Quan Wei, Xiao Hua, Yu Zong ChenAbstract:Increasing numbers of proteins, nucleic acids and other molecular entities have been explored as therapeutic Targets. A challenge in drug discovery is to decide which Targets to pursue from an increasing pool of potential Targets, given the fact that few innovative Targets have made it to the approval list each year. Knowledge of existing drug Targets (both approved and within clinical trials) is highly useful for facilitating Target discovery, selection, exploration and tool development. The Therapeutic Target Database (TTD) has been developed and updated to provide information on 358 successful Targets, 251 clinical trial Targets and 1254 research Targets in addition to 1511 approved drugs, 1118 clinical trials drugs and 2331 experimental drugs linked to their primary Targets (3257 drugs with available structure data). This review briefly describes the TTD Database and illustrates how its data can be explored for facilitating Target and drug searches, the study of the mechanism of multi-Target drugs and...
-
Drug Adverse Reaction Target Database (DART)
Drug Safety, 2003Co-Authors: Zhi Liang Ji, Xin Chen, Yu Zong ChenAbstract:An adverse drug reaction (ADR) often results from interaction of a drug or its metabolites with specific protein Targets important in normal cellular function. Knowledge about these Targets is both important in facilitating the study of the mechanisms of ADRs and in new drug discovery. It is also useful in the development and testing of rational drug design and safety evaluation tools. The Drug Adverse Reaction Database (DART) is intended to provide comprehensive information about adverse effect Targets of drugs described in the literature. Moreover, proteins involved in adverse effect Targets of chemicals not yet confirmed as ADR Targets are also included as potential Targets. This Database gives physiological function of each Target, binding drugs/agonists/antagonists/activators/inhibitors, IC_50 values of the inhibitors, corresponding adverse effects, and type of ADR induced by drug binding to a Target. Cross-links to other Databases are also introduced to facilitate the access of information about the sequence, 3-dimensional structure, function, and nomenclature of each Target along with drug/ligand binding properties, and related literature. The Database currently contains entries for 147 ADR Targets and 89 potential Targets. A total of 187 adverse reaction conditions, 257 drugs, and 1080 ligands known to bind to each of these Targets are also currently described. Each entry can be retrieved through multiple search methods including Target name, Target physiological function, adverse effect, ligand name, and biological pathways. A special page is provided for contribution of new or additional information. This Database can be accessed at http://xin.cz3.nus.edu.sg/group/drt/dart.asp .
-
Drug Adverse Reaction Target Database (DART) : proteins related to adverse drug reactions.
Drug safety, 2003Co-Authors: Lianyi Han, Xin Chen, Chun Wei Yap, Li Zhi Sun, Yu Zong ChenAbstract:An adverse drug reaction (ADR) often results from interaction of a drug or its metabolites with specific protein Targets important in normal cellular function. Knowledge about these Targets is both important in facilitating the study of the mechanisms of ADRs and in new drug discovery. It is also useful in the development and testing of rational drug design and safety evaluation tools. The Drug Adverse Reaction Database (DART) is intended to provide comprehensive information about adverse effect Targets of drugs described in the literature. Moreover, proteins involved in adverse effect Targets of chemicals not yet confirmed as ADR Targets are also included as potential Targets. This Database gives physiological function of each Target, binding drugs/agonists/antagonists/activators/inhibitors, IC50 values of the inhibitors, corresponding adverse effects, and type of ADR induced by drug binding to a Target. Cross-links to other Databases are also introduced to facilitate the access of information about the sequence, 3-dimensional structure, function, and nomenclature of each Target along with drug/ligand binding properties, and related literature. The Database currently contains entries for 147 ADR Targets and 89 potential Targets. A total of 187 adverse reaction conditions, 257 drugs, and 1080 ligands known to bind to each of these Targets are also currently described. Each entry can be retrieved through multiple search methods including Target name, Target physiological function, adverse effect, ligand name, and biological pathways. A special page is provided for contribution of new or additional information. This Database can be accessed at http://xin.cz3.nus.edu.sg/group/drt/dart.asp.
-
TTD: Therapeutic Target Database
Nucleic acids research, 2002Co-Authors: Xin Chen, Yu Zong ChenAbstract:A number of proteins and nucleic acids have been explored as therapeutic Targets. These Targets are subjects of interest in different areas of biomedical and pharmaceutical research and in the development and evaluation of bioinformatics, molecular modeling, computer-aided drug design and analytical tools. A publicly accessible Database that provides comprehensive information about these Targets is therefore helpful to the relevant communities. The Therapeutic Target Database (TTD) is designed to provide information about the known therapeutic protein and nucleic acid Targets described in the literature, the Targeted disease conditions, the pathway information and the corresponding drugs/ligands directed at each of these Targets. Cross-links to other Databases are also introduced to facilitate the access of information about the sequence, 3D structure, function, nomenclature, drug/ligand binding properties, drug usage and effects, and related literature for each Target. This Database can be accessed at http://xin.cz3.nus.edu.sg/group/ttd/ttd.asp and it currently contains entries for 433 Targets covering 125 disease conditions along with 809 drugs/ligands directed at each of these Targets. Each entry can be retrieved through multiple methods including Target name, disease name, drug/ligand name, drug/ligand function and drug therapeutic classification.
Feng Zhu - One of the best experts on this subject based on the ideXlab platform.
-
Therapeutic Target Database update 2014: a resource for Targeted therapeutics.
Nucleic acids research, 2013Co-Authors: Chu Qin, Feng Zhu, Cheng Zhang, Shang Ying Chen, Peng Zhang, Sheng Yong Yang, Yu Quan Wei, Lin TaoAbstract:Here we describe an update of the Therapeutic Target Database (http://bidd.nus.edu.sg/group/ttd/ttd.asp) for better serving the bench-to-clinic communities and for enabling more convenient data access, processing and exchange. Extensive efforts from the research, industry, clinical, regulatory and management communities have been collectively directed at the discovery, investigation, application, monitoring and management of Targeted therapeutics. Increasing efforts have been directed at the development of stratified and personalized medicines. These efforts may be facilitated by the knowledge of the efficacy Targets and biomarkers of Targeted therapeutics. Therefore, we added search tools for using the International Classification of Disease ICD-10-CM and ICD-9-CM codes to retrieve the Target, biomarker and drug information (currently enabling the search of almost 900 Targets, 1800 biomarkers and 6000 drugs related to 900 disease conditions). We added information of almost 1800 biomarkers for 300 disease conditions and 200 drug scaffolds for 700 drugs. We significantly expanded Therapeutic Target Database data contents to cover >2300 Targets (388 successful and 461 clinical trial Targets), 20 600 drugs (2003 approved and 3147 clinical trial drugs), 20,000 multiTarget agents against almost 400 Target-pairs and the activity data of 1400 agents against 300 cell lines.
-
Therapeutic Target Database update 2012: A resource for facilitating Target-oriented drug discovery
Nucleic Acids Research, 2012Co-Authors: Feng Zhu, Chu Qin, Lin Tao, Feng Xu, Xianghui Liu, Zhe Shi, Yang Song, Li Zhang, Xin Liu, Jingxian ZhangAbstract:Knowledge and investigation of therapeutic Targets (responsible for drug efficacy) and the Targeted drugs facilitate Target and drug discovery and validation. Therapeutic Target Database (TTD, http://bidd.nus.edu.sg/group/ttd/ttd.asp) has been developed to provide comprehensive information about efficacy Targets and the corresponding approved, clinical trial and investigative drugs. Since its last update, major improvements and updates have been made to TTD. In addition to the significant increase of data content (from 1894 Targets and 5028 drugs to 2025 Targets and 17,816 drugs), we added Target validation information (drug potency against Target, effect against disease models and effect of Target knockout, knockdown or genetic variations) for 932 Targets, and 841 quantitative structure activity relationship models for active compounds of 228 chemical types against 121 Targets. Moreover, we added the data from our previous drug studies including 3681 multi-Target agents against 108 Target pairs, 116 drug combinations with their synergistic, additive, antagonistic, potentiative or reductive mechanisms, 1427 natural product-derived approved, clinical trial and pre-clinical drugs and cross-links to the clinical trial information page in the ClinicalTrials.gov Database for 770 clinical trial drugs. These updates are useful for facilitating Target discovery and validation, drug lead discovery and optimization, and the development of multi-Target drugs and drug combinations.
-
The Therapeutic Target Database: an internet resource for the primary Targets of approved, clinical trial and experimental drugs.
Expert opinion on therapeutic targets, 2011Co-Authors: Xin Liu, Lin Tao, Jingxian Zhang, Feng Zhu, Sheng Yong Yang, Yu Quan Wei, Xiao Hua, Yu Zong ChenAbstract:Increasing numbers of proteins, nucleic acids and other molecular entities have been explored as therapeutic Targets. A challenge in drug discovery is to decide which Targets to pursue from an increasing pool of potential Targets, given the fact that few innovative Targets have made it to the approval list each year. Knowledge of existing drug Targets (both approved and within clinical trials) is highly useful for facilitating Target discovery, selection, exploration and tool development. The Therapeutic Target Database (TTD) has been developed and updated to provide information on 358 successful Targets, 251 clinical trial Targets and 1254 research Targets in addition to 1511 approved drugs, 1118 clinical trials drugs and 2331 experimental drugs linked to their primary Targets (3257 drugs with available structure data). This review briefly describes the TTD Database and illustrates how its data can be explored for facilitating Target and drug searches, the study of the mechanism of multi-Target drugs and...
-
Update of TTD: Therapeutic Target Database
Nucleic Acids Research, 2009Co-Authors: Feng Zhu, Xianghui Liu, Bu-cong Han, Pankaj Kumar, Xiao Hua, Xiaona Wei, Lu Huang, Yangfan Guo, Lianyi Han, C. J. ZhengAbstract:Increasing numbers of proteins, nucleic acids and other molecular entities have been explored as therapeutic Targets, hundreds of which are Targets of approved and clinical trial drugs. Knowledge of these Targets and corresponding drugs, particularly those in clinical uses and trials, is highly useful for facilitating drug discovery. Therapeutic Target Database (TTD) has been developed to provide information about therapeutic Targets and corresponding drugs. In order to accommodate increasing demand for comprehensive knowledge about the primary Targets of the approved, clinical trial and experimental drugs, numerous improvements and updates have been made to TTD. These updates include information about 348 successful, 292 clinical trial and 1254 research Targets, 1514 approved, 1212 clinical trial and 2302 experimental drugs linked to their primary Targets (3382 small molecule and 649 antisense drugs with available structure and sequence), new ways to access data by drug mode of action, recursive search of related Targets or drugs, similarity Target and drug searching, customized and whole data download, standardized Target ID, and significant increase of data (1894 Targets, 560 diseases and 5028 drugs compared with the 433 Targets, 125 diseases and 809 drugs in the original release described in previous paper). This Database can be accessed at http://bidd.nus.edu.sg/group/cjttd/TTD.asp.
Lin Tao - One of the best experts on this subject based on the ideXlab platform.
-
Therapeutic Target Database update 2014: a resource for Targeted therapeutics.
Nucleic acids research, 2013Co-Authors: Chu Qin, Feng Zhu, Cheng Zhang, Shang Ying Chen, Peng Zhang, Sheng Yong Yang, Yu Quan Wei, Lin TaoAbstract:Here we describe an update of the Therapeutic Target Database (http://bidd.nus.edu.sg/group/ttd/ttd.asp) for better serving the bench-to-clinic communities and for enabling more convenient data access, processing and exchange. Extensive efforts from the research, industry, clinical, regulatory and management communities have been collectively directed at the discovery, investigation, application, monitoring and management of Targeted therapeutics. Increasing efforts have been directed at the development of stratified and personalized medicines. These efforts may be facilitated by the knowledge of the efficacy Targets and biomarkers of Targeted therapeutics. Therefore, we added search tools for using the International Classification of Disease ICD-10-CM and ICD-9-CM codes to retrieve the Target, biomarker and drug information (currently enabling the search of almost 900 Targets, 1800 biomarkers and 6000 drugs related to 900 disease conditions). We added information of almost 1800 biomarkers for 300 disease conditions and 200 drug scaffolds for 700 drugs. We significantly expanded Therapeutic Target Database data contents to cover >2300 Targets (388 successful and 461 clinical trial Targets), 20 600 drugs (2003 approved and 3147 clinical trial drugs), 20,000 multiTarget agents against almost 400 Target-pairs and the activity data of 1400 agents against 300 cell lines.
-
Therapeutic Target Database update 2012: A resource for facilitating Target-oriented drug discovery
Nucleic Acids Research, 2012Co-Authors: Feng Zhu, Chu Qin, Lin Tao, Feng Xu, Xianghui Liu, Zhe Shi, Yang Song, Li Zhang, Xin Liu, Jingxian ZhangAbstract:Knowledge and investigation of therapeutic Targets (responsible for drug efficacy) and the Targeted drugs facilitate Target and drug discovery and validation. Therapeutic Target Database (TTD, http://bidd.nus.edu.sg/group/ttd/ttd.asp) has been developed to provide comprehensive information about efficacy Targets and the corresponding approved, clinical trial and investigative drugs. Since its last update, major improvements and updates have been made to TTD. In addition to the significant increase of data content (from 1894 Targets and 5028 drugs to 2025 Targets and 17,816 drugs), we added Target validation information (drug potency against Target, effect against disease models and effect of Target knockout, knockdown or genetic variations) for 932 Targets, and 841 quantitative structure activity relationship models for active compounds of 228 chemical types against 121 Targets. Moreover, we added the data from our previous drug studies including 3681 multi-Target agents against 108 Target pairs, 116 drug combinations with their synergistic, additive, antagonistic, potentiative or reductive mechanisms, 1427 natural product-derived approved, clinical trial and pre-clinical drugs and cross-links to the clinical trial information page in the ClinicalTrials.gov Database for 770 clinical trial drugs. These updates are useful for facilitating Target discovery and validation, drug lead discovery and optimization, and the development of multi-Target drugs and drug combinations.
-
The Therapeutic Target Database: an internet resource for the primary Targets of approved, clinical trial and experimental drugs.
Expert opinion on therapeutic targets, 2011Co-Authors: Xin Liu, Lin Tao, Jingxian Zhang, Feng Zhu, Sheng Yong Yang, Yu Quan Wei, Xiao Hua, Yu Zong ChenAbstract:Increasing numbers of proteins, nucleic acids and other molecular entities have been explored as therapeutic Targets. A challenge in drug discovery is to decide which Targets to pursue from an increasing pool of potential Targets, given the fact that few innovative Targets have made it to the approval list each year. Knowledge of existing drug Targets (both approved and within clinical trials) is highly useful for facilitating Target discovery, selection, exploration and tool development. The Therapeutic Target Database (TTD) has been developed and updated to provide information on 358 successful Targets, 251 clinical trial Targets and 1254 research Targets in addition to 1511 approved drugs, 1118 clinical trials drugs and 2331 experimental drugs linked to their primary Targets (3257 drugs with available structure data). This review briefly describes the TTD Database and illustrates how its data can be explored for facilitating Target and drug searches, the study of the mechanism of multi-Target drugs and...
Chu Qin - One of the best experts on this subject based on the ideXlab platform.
-
therapeutic Target Database update 2018 enriched resource for facilitating bench to clinic research of Targeted therapeutics
Nucleic Acids Research, 2018Co-Authors: Peng Zhang, Chu Qin, Jing Tang, Qingxia Yang, Xiaoyu Zhang, Xuejiao Cui, Yang Zhang, Fengyuan Yang, Qiu Sun, Xian ZengAbstract:Extensive efforts have been directed at the discovery, investigation and clinical monitoring of Targeted therapeutics. These efforts may be facilitated by the convenient access of the genetic, proteomic, interactive and other aspects of the therapeutic Targets. Here, we describe an update of the Therapeutic Target Database (TTD) previously featured in NAR. This update includes: (i) 2000 drug resistance mutations in 83 Targets and 104 Target/drug regulatory genes, which are resistant to 228 drugs Targeting 63 diseases (49 Targets of 61 drugs with patient prevalence data); (ii) differential expression profiles of 758 Targets in the disease-relevant drug-Targeted tissue of 12 615 patients of 70 diseases; (iii) expression profiles of 629 Targets in the non-Targeted tissues of 2565 healthy individuals; (iv) 1008 Target combinations of 1764 drugs and the 1604 Target combination of 664 multi-Target drugs; (v) additional 48 successful, 398 clinical trial and 21 research Targets, 473 approved, 812 clinical trial and 1120 experimental drugs, and (vi) ICD-10-CM and ICD-9-CM codes for additional 482 Targets and 262 drugs against 98 disease conditions. This update makes TTD more useful for facilitating the patient focused research, discovery and clinical investigations of the Targeted therapeutics. TTD is accessible at http://bidd.nus.edu.sg/group/ttd/ttd.asp.
-
Therapeutic Target Database update 2014: a resource for Targeted therapeutics.
Nucleic acids research, 2013Co-Authors: Chu Qin, Feng Zhu, Cheng Zhang, Shang Ying Chen, Peng Zhang, Sheng Yong Yang, Yu Quan Wei, Lin TaoAbstract:Here we describe an update of the Therapeutic Target Database (http://bidd.nus.edu.sg/group/ttd/ttd.asp) for better serving the bench-to-clinic communities and for enabling more convenient data access, processing and exchange. Extensive efforts from the research, industry, clinical, regulatory and management communities have been collectively directed at the discovery, investigation, application, monitoring and management of Targeted therapeutics. Increasing efforts have been directed at the development of stratified and personalized medicines. These efforts may be facilitated by the knowledge of the efficacy Targets and biomarkers of Targeted therapeutics. Therefore, we added search tools for using the International Classification of Disease ICD-10-CM and ICD-9-CM codes to retrieve the Target, biomarker and drug information (currently enabling the search of almost 900 Targets, 1800 biomarkers and 6000 drugs related to 900 disease conditions). We added information of almost 1800 biomarkers for 300 disease conditions and 200 drug scaffolds for 700 drugs. We significantly expanded Therapeutic Target Database data contents to cover >2300 Targets (388 successful and 461 clinical trial Targets), 20 600 drugs (2003 approved and 3147 clinical trial drugs), 20,000 multiTarget agents against almost 400 Target-pairs and the activity data of 1400 agents against 300 cell lines.
-
Therapeutic Target Database update 2012: A resource for facilitating Target-oriented drug discovery
Nucleic Acids Research, 2012Co-Authors: Feng Zhu, Chu Qin, Lin Tao, Feng Xu, Xianghui Liu, Zhe Shi, Yang Song, Li Zhang, Xin Liu, Jingxian ZhangAbstract:Knowledge and investigation of therapeutic Targets (responsible for drug efficacy) and the Targeted drugs facilitate Target and drug discovery and validation. Therapeutic Target Database (TTD, http://bidd.nus.edu.sg/group/ttd/ttd.asp) has been developed to provide comprehensive information about efficacy Targets and the corresponding approved, clinical trial and investigative drugs. Since its last update, major improvements and updates have been made to TTD. In addition to the significant increase of data content (from 1894 Targets and 5028 drugs to 2025 Targets and 17,816 drugs), we added Target validation information (drug potency against Target, effect against disease models and effect of Target knockout, knockdown or genetic variations) for 932 Targets, and 841 quantitative structure activity relationship models for active compounds of 228 chemical types against 121 Targets. Moreover, we added the data from our previous drug studies including 3681 multi-Target agents against 108 Target pairs, 116 drug combinations with their synergistic, additive, antagonistic, potentiative or reductive mechanisms, 1427 natural product-derived approved, clinical trial and pre-clinical drugs and cross-links to the clinical trial information page in the ClinicalTrials.gov Database for 770 clinical trial drugs. These updates are useful for facilitating Target discovery and validation, drug lead discovery and optimization, and the development of multi-Target drugs and drug combinations.
Peng Zhang - One of the best experts on this subject based on the ideXlab platform.
-
therapeutic Target Database update 2018 enriched resource for facilitating bench to clinic research of Targeted therapeutics
Nucleic Acids Research, 2018Co-Authors: Peng Zhang, Chu Qin, Jing Tang, Qingxia Yang, Xiaoyu Zhang, Xuejiao Cui, Yang Zhang, Fengyuan Yang, Qiu Sun, Xian ZengAbstract:Extensive efforts have been directed at the discovery, investigation and clinical monitoring of Targeted therapeutics. These efforts may be facilitated by the convenient access of the genetic, proteomic, interactive and other aspects of the therapeutic Targets. Here, we describe an update of the Therapeutic Target Database (TTD) previously featured in NAR. This update includes: (i) 2000 drug resistance mutations in 83 Targets and 104 Target/drug regulatory genes, which are resistant to 228 drugs Targeting 63 diseases (49 Targets of 61 drugs with patient prevalence data); (ii) differential expression profiles of 758 Targets in the disease-relevant drug-Targeted tissue of 12 615 patients of 70 diseases; (iii) expression profiles of 629 Targets in the non-Targeted tissues of 2565 healthy individuals; (iv) 1008 Target combinations of 1764 drugs and the 1604 Target combination of 664 multi-Target drugs; (v) additional 48 successful, 398 clinical trial and 21 research Targets, 473 approved, 812 clinical trial and 1120 experimental drugs, and (vi) ICD-10-CM and ICD-9-CM codes for additional 482 Targets and 262 drugs against 98 disease conditions. This update makes TTD more useful for facilitating the patient focused research, discovery and clinical investigations of the Targeted therapeutics. TTD is accessible at http://bidd.nus.edu.sg/group/ttd/ttd.asp.
-
MYCN Amplification Is Associated with Repressed Cellular Immunity in Neuroblastoma: An In Silico Immunological Analysis of Target Database.
Frontiers in immunology, 2017Co-Authors: Peng Zhang, Moushumi Basu, Chen Dong, Pan Zheng, Yang Liu, Anthony David SandlerAbstract:Purpose RNA and DNA sequencing data are traditionally used to discern intrinsic cellular pathways in cancer pathogenesis, their utility for investigating the tumor microenvironment has not been fully explored. This study explores the use of sequencing data to investigate immunity within the tumor microenvironment. Experimental design Here we use immune cell fraction estimation analysis to determine the immune profiles in the microenvironment of neuroblastoma based on RNAseq data in the Target Database. The correlation between immune cell transcripts and prognosis in pediatric neuroblastoma is also investigated. Results In silico analysis revealed a strong inverse correlation between MYCN amplification and leukocyte infiltration. This finding was validated by immunohistochemistry analysis in tumor samples. Moreover, the abundance of CD4 T cells strongly associated with better patient survival regardless of MYCN gene amplification, while those of CD8 T cells, NK or B cells do not. Based on characteristic cytokine expression of CD4 subsets in tumors, the Th2 rather than Th1 levels were associated with better prognosis. Conclusion We found that the in silico analysis of Target Database reflected tumor immunity and was validated by the immuno-histochemical tumor data. Our results reveal the association of MYCN amplification with repressed cellular immunity and the potential prognostic value of infiltrating CD4 T cell transcripts in pediatric neuroblastoma. This analysis illustrates the potential role of MYCN in neuroblastoma as a regulator of immune privilege and characterizes the power of in silico analysis for delineating cancer immunology and risk stratification.
-
Therapeutic Target Database update 2014: a resource for Targeted therapeutics.
Nucleic acids research, 2013Co-Authors: Chu Qin, Feng Zhu, Cheng Zhang, Shang Ying Chen, Peng Zhang, Sheng Yong Yang, Yu Quan Wei, Lin TaoAbstract:Here we describe an update of the Therapeutic Target Database (http://bidd.nus.edu.sg/group/ttd/ttd.asp) for better serving the bench-to-clinic communities and for enabling more convenient data access, processing and exchange. Extensive efforts from the research, industry, clinical, regulatory and management communities have been collectively directed at the discovery, investigation, application, monitoring and management of Targeted therapeutics. Increasing efforts have been directed at the development of stratified and personalized medicines. These efforts may be facilitated by the knowledge of the efficacy Targets and biomarkers of Targeted therapeutics. Therefore, we added search tools for using the International Classification of Disease ICD-10-CM and ICD-9-CM codes to retrieve the Target, biomarker and drug information (currently enabling the search of almost 900 Targets, 1800 biomarkers and 6000 drugs related to 900 disease conditions). We added information of almost 1800 biomarkers for 300 disease conditions and 200 drug scaffolds for 700 drugs. We significantly expanded Therapeutic Target Database data contents to cover >2300 Targets (388 successful and 461 clinical trial Targets), 20 600 drugs (2003 approved and 3147 clinical trial drugs), 20,000 multiTarget agents against almost 400 Target-pairs and the activity data of 1400 agents against 300 cell lines.
